Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Who should get COVID-19 vaccines first? CDC advisors have ideas

By Brian Buntz | November 24, 2020

Immunization

[Image from National Cancer Institute via Unsplash]

An estimated 21 million U.S. healthcare workers should be among the first to receive a COVID-19 vaccine, according to a CDC advisory committee.

The Advisory Committee on Immunization Practices (ACIP) within the CDC met yesterday to discuss how to best allocate COVID-19 vaccines. Members of the group will formalize their recommendations by voting after FDA approves or authorizes COVID-19 vaccines. CDC will then look to that guidance as it creates recommendations for immunization schedules.

Achieving the committee’s goal of immunizing healthcare workers first may not be as straightforward as it seems. Some healthcare workers are hesitant about receiving a COVID-19 vaccine, mirroring a broader trend across the public.

A recent survey of healthcare workers in Los Angeles found that 66.5% actually plan to hold off on getting vaccinated. Reasons for the intent to delay include evolving SARS-CoV-2 science (76.0%), the current political climate (57.6%) and the rapid pace of COVID-19 vaccine development (83.4%).

Nurses in the study were 4.15 times more likely to intend delaying their vaccination while other workers in patient-contact roles were 2.45 times more likely to do so.

A poll in New Jersey found that only two-thirds of doctors and 47% of nurses would be willing to take the COVID-19 vaccine.

Healthcare workers’ willingness to be vaccinated could increase — following the positive results from Pfizer (NYSE:PFE) and its partner BioNTech (NSDQ:BNTX) in addition to Moderna (NSDQ:MRNA).

FDA’s decision to approve or authorize COVID-19 vaccines before the end of the year with will be another “step-up in perception” among healthcare providers —  along with associated labeling information — according to UBS analyst Navin Jacob.

The CDC advisory panel also stressed the importance of making COVID-19 vaccines readily available for other types of essential workers, seniors and nursing home residents, diverse populations and lower-income people.

Incidentally, only 40% of older adults who are Black, and 51% of those who are Hispanic are likely to get a COVID-19 vaccine, according to a University of Michigan survey.

The committee concluded that vaccines are a cost-effective strategy in fighting the pandemic. Healthcare members estimated the cost of treating COVID-19 could hit $163 billion if 20% of the U.S. public is infected. The virus’s ultimate financial toll could hit $8.3 trillion when considering the cost of premature deaths and long-term mental impairment.

But the actual cost of COVID-19 vaccines is relatively trivial. The BNT162b2 vaccine candidate from BioNTech and Pfizer costs $39 per dose, which is on par with a flu shot.


Filed Under: Infectious Disease
Tagged With: ACIP, Advisory Committee on Immunization Practices, CDC, coronavirus, covid-19, COVID-19 vaccine, FDA, U.S. Centers for Disease Control and Prevention (CDC)
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
Novel coronovirus
Advances in next generation vaccine development for SARS-CoV-2
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE